PPIDT00335
Drug Information
| Name | Polatuzumab vedotin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB12240 |
| Type | biotech |
| Indication | Polatuzumab vedotin is used in combination with [bendamustine] and [rituximab] to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.[L6658] In Canada, this indication is approved for patients who are not eligible for autologous stem cell transplant and have received at least one prior therapy.[L44141] Polatuzumab vedotin is also used in combination with [rituximab], [cyclophosphamide], [doxorubicin], and [prednisone] (R-CHP) to treat adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high-grade B-cell lymphoma,[L44141, L46013] Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL.[L44141] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
140 mg
|
| Injection, powder, for solution | Intravenous |
30 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
140 mg/7.52mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
30 mg/1.88mL
|
| Injection, solution, concentrate | Intravenous |
140 mg/1vial
|
| Powder, for solution | Intravenous |
140 mg / vial
|
| Powder, for solution | Intravenous |
30 mg / vial
|
| Powder | — |
140 mg
|
| Powder | — |
30 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
140 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
30 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P40259 | CD79B | B-cell antigen receptor complex-associated protein beta chain | Homo sapiens | antibody | Link |
| enzyme | P08684 | CYP3A4 | Cytochrome P450 3A4 | Homo sapiens | substrate | Link |
| enzyme | P20815 | CYP3A5 | Cytochrome P450 3A5 | Homo sapiens | substrate | Link |
| transporter | P08183 | ABCB1 | ATP-dependent translocase ABCB1 | Homo sapiens | substrate | Link |